Diabetes COBRE

SECTION OF ENDOCRINOLOGY AND DIABETES
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
LINE
HOME | Principal Investigator | Associate Director |PJIs | CORES | MENTORS | IAC | EAC | PROJECTS | CALENDAR
LINE

The Principal Investigator


Jian-xing Ma, MD, PhD

Jian-xing Ma, MD, PhD, Laureate Professor and Chairman of the Department of Physiology, graduated from Jiangxi Medical College in China and received his Ph.D. in Biochemistry and Molecular Biology at the Medical University of South Carolina. The combination of his medical background and solid training in basic sciences enables him to apply his molecular biological skills in the investigation of human diseases. He has focused on diabetic complications since 1994 and has a long track record of independent funding in diabetes research from the NIH, American Diabetes Association (ADA) and Juvenile Diabetes Research Foundation (JDRF). His group has made significant contributions to the study of diabetic microvascular complications. He was the first to show experimentally that the balance between pro-angiogenic factors and angiogenic inhibitors is the key determinant of ocular and renal inflammation and angiogenesis, and that a disturbed balance between pro-angiogenic factors and angiogenic inhibitors in diabetes plays a key pathogenic role in diabetic retinopathy and nephropathy. Further, his group showed that delivery of these angiogenic inhibitors into diabetic rats significantly ameliorated retinal vascular leakage, neovascularization, proteinuria, mesangial expansion, and inflammation in the kidney. His group was the first to show genetic differences in susceptibility to diabetic retinopathy in animal models. His group was also the first to identify retinal isomerohydrolase, a key enzyme in the visual cycle of vitamin A processing and an enzyme sought for by the vision community for over 20 years. Recently, his group demonstrated for the first time that the aberrant activation of the Wnt pathway represents a common pathogenic mechanism for diabetic retinopathy and nephropathy and represents a novel target for therapies. He has been invited to present his research at numerous national and international conferences and at numerous institutions in different countries. He has served as a reviewer in a number of NIH study sections and for the Department of Veterans Affairs and NSF. He has also served on grant review panels for foundations in several countries, including panels at ADA, JDRF, Austrian Science Fund (FWF), UK Fight for Sight, Chinese Natural Science Foundation, Diabetes UK, Dutch Diabetes Research Foundation, and King Abdulaziz City for Science and Technology.

            The PI is also currently conducting collaborative and translational research with colleagues at OUHSC and at other universities across the US and abroad. He is collaborating with clinicians in clinical studies, such as Dr. Timothy Lyons and Dr. Alicia Jenkins, in searching for predictive markers of diabetic complications. He has obtained two Partnership Grants from NIH and JDRF in diabetes research. He was also the PI of a NIH bench-to-bedside grant to develop a new treatment for diabetic retinopathy. His group has recently developed a humanized antibody to block the Wnt pathway and demonstrated its therapeutic potential for diabetic complications. This antibody has been patented through OU and was recently licensed to a private company for further development into a clinical drug for diabetic complications. He has two other pending patents, both in the diabetes field. His translational research has been funded by the Oklahoma Economic Development Generating Excellence (EDGE) Program and recommended for funding in NIH Rapid Access to Interventional Development (RAID) program to complete FDA-required studies for initiation of a Phase I clinical trial of another drug candidate.

            The PI has a long track record in mentoring graduate students, postdoctoral fellows and junior faculty members. He has trained 16 graduate students and 37 postdoctoral fellows in his lab, 12 of which have become faculty in academic institutions. In addition, he has trained two professors from teaching colleges. One of the professors has continued the project she initiated in Dr. Ma’s lab and has obtained an independent NSF grant. He has also served as a mentor for two PJIs in the OUHSC Vision COBRE. The PI has participated in numerous administrative activities, including serving as a member of OUHSC Strategic Planning, as a member of OUHSC Research Council, and as Chairman of the first Internal Review Committee for a Graduate Program. He initiated and has been organizing the state-wide annual Diabetes Research Retreat for the last seven years, which last year had 115 attendees and 55 presentations, and has served as the PI of the COBRE and Director of Diabetic Animal Core since 2007. In 2010, he was selected to become Chairman of the Department of Physiology. A major goal of his new position is to expand research in the Department of Physiology by mentoring junior investigators and by recruiting new faculty members into Oklahoma. He recruited two strong faculty members to Oklahoma in 2010 and is in the process of recruiting three more.

 
LINE
« back | home
LINE